Format

Send to

Choose Destination
Kidney Int. 2009 Nov;76(9):925-8. doi: 10.1038/ki.2009.325.

Vasopressin in chronic kidney disease: an elephant in the room?

Author information

1
Mayo Clinic College of Medicine, Rochester, MN 55905, USA. torres.vicente@mayo.edu

Abstract

Perico et al. report that a dual arginine vasopressin (AVP) V(2) and V(1a) receptor antagonist lowers blood pressure, proteinuria, and glomerulosclerosis in 5/6 nephrectomized rats, pointing to its potential value in the treatment of chronic kidney disease (CKD). AVP likely contributes to CKD progression by its effects on renal hemodynamics, blood pressure, and mesangial and/or epithelial cells, but the relative contributions of V(2) and V(1a) receptors and potential usefulness of V(2) and V(1a) receptor antagonists remain ill defined.

PMID:
19829311
PMCID:
PMC2925670
DOI:
10.1038/ki.2009.325
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center